A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

Summary

The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).

Timeline

Start

2025-11-18

Primary completion

2026-06-14

Completion

2026-07-13

Drugs

Indications